ASPI · ASP Isotopes Inc. Common Stock

Revenue surged to $23.8 million in FY2025, a 475.5% increase from $4.1 million in the prior year, as the Company diversified beyond traditional isotopes into construction services and nuclear medical doses. This topline transformation reflects execution on growth initiatives, though revenues from helium and LNG remain volatile due to fluctuating production volumes and commodity prices. Gross profit rose to $3.4 million (112.9% YoY) at a 14.3% margin, with cost of revenue tied to subcontracting, staff, and materials expensed as incurred—highlighting the capital-intensive nature of scaling operations.

Operating income swung deeper into loss at -$59.9 million (-127.3% YoY), as expenses escalated with R&D investments in future isotopes, which management expects to increase substantially. The Company has incurred net losses and negative operating cash flows since inception, a pattern that deepened with FY2025's -$37.8 million operating cash outflow (versus -$16.7 million prior), yielding free cash flow of -$47.4 million after $9.7 million in capital expenditures primarily for enrichment facilities. Net income deteriorated sharply to -$159.8 million (-393.0% YoY), with diluted EPS at -$2.11, underscoring the impact of non-cash charges amid business expansion.

Strategic moves include loan amendments, such as extending the Renergen repayment to on-demand terms post-January 2026 and variable-rate SBSA financing with compounding interest. These reflect proactive capital management amid growth, but underscore execution risks in a high-investment phase. Investors should monitor R&D trajectory and revenue volatility as key drivers of path to profitability.